Does Shingrix (recombinant varicella‑zoster glycoprotein E vaccine) contain any components that are also present in seasonal influenza vaccines or COVID‑19 vaccines, given the patient experienced drug‑induced liver injury after Shingrix and is hesitant to receive another vaccine?

Shingrix and Other Vaccines: Shared Components Analysis

Shingrix does not share the same active viral antigens with seasonal influenza or COVID-19 vaccines, but it does contain polysorbate 80, an excipient also found in some COVID-19 vaccines, which could theoretically be a shared allergen. However, the adjuvant system (AS01B) in Shingrix is unique and not present in standard flu or COVID vaccines, making cross-reactivity with the specific immune-stimulating components unlikely 1.

Component Breakdown

Shingrix-Specific Components

Shingrix contains 1:

• Recombinant varicella zoster virus glycoprotein E (gE) - unique to this vaccine
• AS01B adjuvant system containing:
  • MPL (3-O-desacyl-4'-monophosphoryl lipid A)
  • QS-21 (saponin from Quillaja saponaria)
  • Liposomal formulation (DOPC and cholesterol)
• Polysorbate 80 (0.08 mg per dose)
• Various stabilizers and salts

Potential Overlap with Other Vaccines

COVID-19 vaccines:

• mRNA vaccines (Pfizer, Moderna) contain polysorbate or polyethylene glycol (PEG) as stabilizers 2
• Viral vector vaccines (J&J, AstraZeneca) contain polysorbate 2
• None contain the AS01B adjuvant system unique to Shingrix

Influenza vaccines:

• Standard inactivated influenza vaccines typically do NOT contain polysorbate 80
• Some formulations may contain polysorbate 80 as a stabilizer, but this varies by manufacturer 3
• Adjuvanted flu vaccines (like Fluad with MF59) use different adjuvant systems than Shingrix 3

Drug-Induced Liver Injury Context

Critical Considerations for Your Patient

The patient's DILI from Shingrix creates a complex risk assessment scenario. The 2025 British Society of Gastroenterology guidelines note that several cases of autoimmune hepatitis-like illness have been reported within 4 weeks of COVID-19 vaccination (both viral vector and mRNA types), though the incidence is low at approximately 4 per 10,000 4. Importantly, in some reports, liver injury developed twice after repeated exposure to the same vaccine, although not after re-exposure to a different vaccine 4.

Evidence on Vaccine-Associated Liver Injury

COVID-19 vaccines:

• Rare cases of immune-mediated liver injury reported, typically presenting as autoimmune hepatitis-like illness 4
• Most cases are mild and respond to corticosteroids 4
• Incidence: approximately 4 per 10,000 vaccinations 4
• Key finding: Different vaccine platforms (mRNA vs viral vector) may have different risk profiles for the same individual 4

Influenza vaccines:

• A 2024 study comparing COVID-19 and influenza vaccines found cumulative incidence of new-onset liver enzyme elevation at 90 days was 4.7 per 1000 for COVID-19 vaccines versus 5.1 per 1000 for influenza vaccines (not statistically different, p=0.489) 5
• Standard inactivated influenza vaccines have minimal association with liver injury

Clinical Recommendations

Risk Stratification

Your patient's DILI from Shingrix does NOT automatically predict liver injury from flu or COVID vaccines because:

1. The AS01B adjuvant system in Shingrix is unique and likely the primary immune trigger 1
2. The recombinant gE antigen is specific to varicella zoster and not present in other vaccines 1
3. Evidence suggests vaccine platform matters - switching vaccine types may reduce risk 4

Specific Guidance by Vaccine Type

For COVID-19 vaccination:

• Consider mRNA vaccines (Pfizer/Moderna) over viral vector vaccines if the patient needs COVID vaccination, as switching vaccine platforms has shown reduced risk of repeat liver injury 4
• The shared polysorbate component is present in minimal amounts and rarely implicated in liver injury
• Monitor liver enzymes at baseline, 2 weeks, and 4 weeks post-vaccination 4
• If liver injury occurs, it typically presents within 4 weeks and usually responds to corticosteroids 4

For influenza vaccination:

• Standard inactivated or recombinant influenza vaccines are recommended 3
• These have the lowest theoretical cross-reactivity with Shingrix components
• Avoid adjuvanted influenza vaccines (like Fluad with MF59) to minimize exposure to novel adjuvant systems 3
• The risk of liver injury from standard flu vaccines appears comparable to or lower than COVID vaccines 5

Monitoring Protocol

If proceeding with vaccination:

1. Obtain baseline liver function tests (ALT, AST, bilirubin, alkaline phosphatase)
2. Repeat LFTs at 2 weeks and 4 weeks post-vaccination 4
3. Educate patient on symptoms: jaundice, dark urine, severe fatigue, right upper quadrant pain
4. If transaminases rise >2x baseline or >3x ULN, consider hepatology referral 4

Important Caveats

The overall benefit-risk calculation strongly favors vaccination for both COVID-19 and influenza, especially given:

• The patient's prior DILI from Shingrix was likely adjuvant-mediated, not a general vaccine hypersensitivity
• COVID-19 and influenza pose significant morbidity/mortality risks
• Vaccine-associated liver injury, when it occurs, is usually self-limited or steroid-responsive 4, 5, 6

Document the patient's Shingrix DILI history in the medical record and report any subsequent vaccine-related liver injury to VAERS (Vaccine Adverse Event Reporting System) to contribute to pharmacovigilance 7.